Full-length CD4 electroinserted in the erythrocyte membrane as a long-lived inhibitor of infection by human immunodeficiency virus. by M Zeira et al.
Proc. Natl. Acad. Sci. USA
Vol. 88, pp. 4409-4413, May 1991
Biophysics
Full-length CD4 electroinserted in the erythrocyte membrane as a
long-lived inhibitor of infection by human immunodeficiency virus
(life span of CD4 in erythrocytes/human immunodeficiency virus type 1 inactivation/fluorescence dequenching/reverse transcriptase/
p24 core antigen)
MICHAEL ZEIRA*, PIERRE-FRANgOIS Tosit, YOUSSEF MOUNEIMNEt, JAIME LAZARTEt, LOYD SNEEDt,
DAVID J. VOLSKY*, AND CLAUDE NICOLAUt*
*Molecular Virology Laboratory, St. Luke's/Roosevelt Hospital Center and College of Physicians & Surgeons, Columbia University, 432 West 58th Street,
New York, NY 10019; and tCell Biology Section, Institute of Biosciences and Technology, Texas A&M University, College Station, TX 77843-2401
Communicated by Charles J. Arntzen, February 19, 1991
ABSTRACT Recombinant full-length CD4 expressed in
Spodopterafrugiperda 9 cells with the baculovirus system was
electroinserted in erythrocyte (RBC) membranes. Of the in-
serted CD4, 70% was "correctly" oriented as shown by
fluorescence quenching experiments with fluorescein-labeled
CD4. The inserted CD4 displayed the same epitopes as the
naturally occurring CD4 in human T4 cells. Double-labeling
experiments (12'I-CD4 and 51Cr-RBC) showed that the half-life
of CD4 electroinserted in RBC membrane in rabbits was
approximately 7 days. Using the fluorescence dequenching
technique with octadecylrhodamine B-labeled human immu-
nodeficiency virus (HIV)-1, we showed fusion of the HIV
envelope with the plasma membrane ofRBC-CD4, whereas no
such fusion could be detected with RBC. The dequenching
efficiency of RBC-CD4 is the same as that of CEM cells.
Exposure to anti-CD4 monoclonal antibody OKT4A, which
binds to the CD4 region that attaches to envelope glycoprotein
gp120, caused a significant decrease in the dequenching of
fluorescence. In vitro infectivity studies showed that preincuba-
tion of HIV-1 with RBC-CD4 reduced by 80-90% the appear-
ance ofHIV antigens in target cells, the amount of viral reverse
transcriptase, and the amount ofp24 core antigen produced by
the target cels. RBC-CD4, but not RBCs, aggregated with
chronically HIV-i-infected T cells and caused formation of
giant cells. These data show that the RBC-CD4 reagent is
relatively long lived in circulation and efficient in attaching to
HIV-1 and HIV-infected cells, and thus it may have value as a
therapeutic agent against AIDS.
Although soluble CD4 (sCD4) acts efficiently in blocking
human immunodeficiency virus (HIV) infection in vitro (1-5)
and simian immunodeficiency virus (SIV) infection in rhesus
monkeys (6), it appeared that very high amounts ofsCD4 may
be required in humans to achieve "therapeutic concentra-
tions" (6), largely due to its short half-life (7). There might be,
therefore, a significant advantage in having a CD4 carrier that
is long-lived in circulation and capable of both clearing free
HIV and binding to HIV-infected cells (8). The latter could
form aggregates that would be removed from circulation by
phagocytosis by the reticuloendothelial system (8).
The human erythrocyte (red blood cell; RBC), with a
half-life ofabout 2 months, appears to be a good candidate for
a long-lived CD4 carrier in the circulation (9). We have
developed a method to electroinsert xenoproteins into RBC
membranes that preserves protein epitopes and stability in
circulation of the RBC-protein conjugate (10, 11). We then
expressed the full-length CD4 molecule (which includes the
membrane-spanning sequence) in insect cells (Spodoptera
frugiperda isolate 9), using the baculovirus expression vector
system (12). Recombinant CD4 was isolated by immunoaf-
finity chromatography (12) and was inserted in rabbit RBC
membranes by electroinsertion (11). It showed patching upon
monoclonal antibody (mAb) binding and displayed the same
anti-CD4 monoclonal epitope map as CD4 expressed byCEM
cells (a line of human T leukemia cells), just as was the case
with CD4 inserted in mouse or human cells (11).
We report here that when inserted into rabbit RBC mem-
branes, CD4 is relatively long-lived in circulation. Moreover,
we show that human RBC-CD4 can attach to HIV-1 particles
and fuse with their envelopes, inhibit HIV infection of
susceptible target cells, and aggregate HIV-infected cells that
expose the HIV envelope glycoprotein gp120 on their plasma
membranes.
MATERIALS AND METHODS
Expression and Purification of Full-Length CD4. A cDNA
encoding full-length CD4 (gift from R. Axel, Columbia Uni-
versity, New York, NY) was inserted into the genome of
Autographa californica nuclear polyhedrosis virus under
transcriptional regulation of the viral polyhedrin gene pro-
moter. The recombinant virus was used to infect insect cells,
resulting in the abundant expression of CD4 as evaluated by
flow cytometry and immunoblot analysis (12). Recombinant
CD4 expressed on the surface of infected insect cells was
immunologically indistinguishable from human T-cell surface
CD4 when tested with 11 different anti-CD4 mAbs. Sequen-
tial phase-transition separation with Triton X-114, immunoaf-
finity chromatography, NaDodSO4/PAGE, and silver stain-
ing revealed that infected cells express a single CD4 protein
(12). Immunoblot analysis under nondenaturing conditions
showed that the purified protein reacted with the anti-CD4
mAb Leu-3a (12).
Electroinsertion of CD4 in the RBC Membrane. The pro-
cedure was performed as described (11). Briefly, we em-
ployed a 606 Cober pulse generator, a cylindrical Teflon
chamber 1.2 cm in diameter, with each end formed by 1.2 cm
x 2.5 cm stainless steel electrodes, the electrode gap being
0.2 cm. Potential and current were monitored by a Nicolet
2090 digital oscilloscope. During the experiment, the elec-
troinsertion chamber was maintained at 37°C by using a
circulating water thermostat. RBCs, obtained from a blood
bank, were separated from fresh whole blood of healthy
donors with citrate buffer as anticoagulant. The RBCs were
washed three times with the electroinsertion medium (0.14 M
Abbreviations: RBC, red blood cell; HIV, human immunodeficiency
virus; CD4, receptor for HIV-1 on human T4 cells; sCD4, soluble
CD4; R 18, octadecylrhodamine B chloride; mAb, monoclonal
antibody; FITC, fluorescein isothiocyanate; DQ, dequenching.
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NaCi and 10 mM HNa2PO4/H2NaPO4 adjusted to pH 8.8
with NaOH), and a RBC stock suspension of 2 x 109 cells per
ml was prepared. Highly purified, 1yophilized, full-length
CD4 obtained in our laboratory (12) was dissolved in the
electroinsertion medium. The CD4 solution, at 1 mg/ml, was
added to the RBC suspension. After 20-min incubation on
ice, the solution was brought to 370C and four square elec-
trical pulses of 1 ms each were applied at 15-min intervals.
The field intensity was 1.3 kV/cm for human RBCs and 2.1
kV/cm for mouse RBCs. After pulse application, the cells
were washed three times with phosphate-buffered saline
(PBS), pH 7.4, and stored at 40C.
Orientation of CD4 Electroinserted in the RBC Membrane.
To assess the orientation of the CD4 molecules in the RBC
membrane after electroinsertion, CD4 was conjugated with
fluorescein isothiocyanate (FITC) prior to insertion. Briefly,
CD4 at 4 mg/ml in 0.25 M borax/boric acid, pH 8.0, was
incubated with FITC (Sigma) at 100 ,ug/mg of protein. After
4 hr on ice, free fluorescein was removed by chromatography
on Sephadex G-25 (Pharmacia). The FITC-CD4 fraction was
collected, concentrated (Amicon Micropartition System,
Amicon), and lyophilized. For the quenching studies, 107
RBC-CD4-FITC were incubated with anti-FITC antibodies
(Molecular Probes) for 20 min then diluted and analyzed for
their green fluorescence. Flow cytometry was performed in
a Coulter Epics Profile instrument. The percentage of
quenching by anti-FITC antibodies was estimated according
to the mean peak fluorescence of the different samples.
Life-Span Measurements of CD4 Inserted in RBC Mem-
branes in Rabbits. Purified CD4 (250 ,ug) was labeled with 500
,uCi (1 ,uCi = 37 kBq) of Bolton-Hunter 125i reagent (13) for
2 hr at 4°C. Labeled CD4 was purified on a Sephadex G-25
column. Glycophorin (1 mg) was labeled with 250 ,uCi of 1251
by following the same procedure. 125I-CD4 or 1251.
glycophorin was electroinserted into 700 1jI of packed rabbit
RBC membranes (11). 1251I assay indicated that =5000 mol-
ecules ofCD4 were inserted per RBC. Epitopes were assayed
by flow cytometry using unlabeled CD4 as a control. After
insertion, the RBC-CD4 were labeled (14) with 5 ,Ci of 51Cr,
resuspended in plasma, and transfused with a 22-gauge
Teflon-coated needle catheter into autologous New Zealand
White rabbits weighing 2.7-2.9 kg that were anesthetized
with ketamine at 25 mg/kg and xylazine at 2 mg/kg. At the
indicated time, 1.5 ml of blood was drawn from the marginal
ear vein of the rabbit.
Measurement of Fusion of HIV-1 Envelope with RBC-CD4
by Using the Membrane Fluorescence Dequenching (DQ) Tech-
nique' HIV-1 was propagated in chronically infected H9 cells
and infection was monitored by reverse transcriptase activity
and by immunofluorescence assay of HIV-1 antigens. Con-
centrated virus was purified by centrifugation through a
20-60% sucrose gradient. Intact virions were labeled with
octadecylrhodamine B chloride (R 18; Molecular Probes) as
described (15); 0.6 ,l of a 1 mg/ml ethanolic solution of R 18
was rapidly added to 50 ,ug of HIV-1. After 15-min incubation
at room temperature, virus was separated from free dye by
centrifugation. Labeled virions (R-18-HIV-1) were resus-
pended in PBS to a final concentration of 0.5 mg of viral
protein per ml. R-18-HIV-1 was adsorbed to target cells in 100
,ul of RPMI 1640 medium/5% fetal bovine serum for 5-7 min
at 4°C followed by washing off unadsorbed virus and incu-
bation at 37°C for an additional 25 min. Cells were then
diluted to 3 ml with RPMI 1640 medium and analyzed for
fluorescence by using a Perkin-Elmer LS-3B fluorescence
spectrophotometer (560-nm excitation, 590-nm emission),
first without any treatment to obtain the actual fluorescence
value and then with 0.15% Triton X-100 to elute the R 18 from
membranes and to determine the maximum fluorescence
associated with these membranes. The background fluores-
cence value was measured on a mixture of R-18-HIV-1 and
target cells at zero time. Specific DQ was calculated as a
proportion of actual system fluorescence to 100lo fluores-
cence value, after subtracting the background fluorescence.
A 2.5-,ug sample of R-18-HIV-1 was incubated with the
designated amounts of RBC-CD4, RBC-CD4 saturated with
OKT4A mAb, control RBC, or CD4-positive cell lines CEM
and CR10 as controls. When fusion between the labeled virus
and the target cells occurred, an increase in fluorescence
signal (i.e., fluorescence DQ) was observed that was directly
proportional to the extent of virus-cell fusion (15-19).
Infectivity of HIV-1 after Preincubation with RBC-CD4.
RBC-CD4, RBC-CD4/OKT4A, or untreated RBCs (1.5 x 109
cells each), or 1.5 x 108 CEM cells were suspended in 0.5 ml
of RPMI-1640 medium and mixed with 20 .ul of concentrated
HIV-1IIIB (8.85 jug of viral p24 per ml), or the same amount
of virus was mixed with 0.5 ml of PBS. The mixtures were
incubated for 15 min at 40C for viral adsorption, followed by
30 min at 370C for viral fusion. Cells were removed by
centrifugation; supernatants containing free virus were fil-
tered through 0.45-ptm filters to ensure sterility, and 0.25 ml
of each was used for infection of 0.2 x 106 C-8166 (HTLV-
I-immortalized cord blood lymphocytes) or CEM cells ac-
cording to a standard protocol (19). Infection was evaluated
on days 6, 9, and 12 after addition of supernatant by mea-
suring (i) the levels of HIV-1 reverse transcriptase activity
and HIV-1 p24 core antigens in culture supernatants; and (it)
the proportion of cells expressing intracellular HIV-1 anti-
gens, as determined by HIV-i-specific immunofluorescence
assay (19). HIV-1 p24 capsid protein was detected by using
Coulter HIV Ag Assay (Coulter).
RESULTS
Orientation of Electroinserted CD4 Molecules. Electroin-
sertion is not expected to result in all CD4 molecules being
exposed in the native orientation. To determine the fre-
quency of "correctly" oriented CD4 molecules on the sur-
face of the RBC, FITC was covalently attached to CD4 prior
to electroinsertion. The number of FITC-CD4 molecules per
cell was determined by cytofluorimetric assay, then the
RBC-CD4-FITC were exposed to anti-FITC antibodies. Cyto-
fluorimetric assay of the fluorescence emission indicated that
73% of the fluorophores were quenched by the anti-FITC
0
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FIG. 1. Quenching of RBC-CD4-FITC fluorescence by anti-
FITC antibodies. Flow cytometry histograms (green fluorescence) of
RBCs with FITC-CD4 inserted in their membrane (-); quenching of
the same RBC-CD4-FITC after incubation with anti-FITC antibodies
--- -); and control RBCs ( *. FITC was covalently bound to CD4.
Flow cytometry was performed in a Coulter Epics Profile instrument.
The percentage of quenching by anti-FITC antibodies was estimated
according to the mean peak fluorescence of the different samples
(RBC control, 4.78; RBC-CD4-FITC-anti-FITC, 5.74; and RBC-
CD4-FITC, 7.09).
4410 Biophysics: Zeira et al.
Proc. Natl. Acad. Sci. USA 88 (1991) 4411
antibodies (Fig. 1), indicating that most of the inserted CD4
was available for interactions with ligands.
Life-Span Measurements of RBC-CD4 in Rabbits. To per-
form the life-span measurement, full-length CD4 was labeled
with 125I and inserted into rabbit RBC membranes. The RBCs
were then labeled with 51Cr so that the life span ofthe cell and
that of the inserted protein could be measured simultane-
ously. As a control, human glycophorin A was labeled with
1251 and inserted by the same technique. Radioactivity mea-
surement indicated the presence of about 6000 molecules of
glycophorin per RBC. Autologous transfusions of 51Cr-RBC-
1251-CD4 (two animals) and 51Cr-RBC-1251-glycophorin (two
animals) were performed and the 1251 and 51Cr radioactivity
were measured at different time points. Fig. 2 shows these
radioactivities as a function of time. Whereas the radioac-
tivity measurements of 51Cr indicate a half-life of about 16
days for the rabbit RBC, the 1251 measurements indicate a
half-life of about 7 days for the inserted CD4 or glycophorin
(Fig. 2). Both proteins show the same half-life, shorter than
that of the "carrier" but significantly longer than the values
obtained for free sCD4, hybrid sCD4 injected i.v. (7), or sCD4
injected intramuscularly (6). During 30 days of observation,
no immune response against either inserted CD4 or glyco-
phorin could be detected in the injected rabbits, whereas the
free proteins injected i.v. in the same amounts elicited a
strong immune response (data not shown).
Fusion of HIV-1 Envelopes with the Membrane of RBC-
CD4. To determine whether CD4 molecules inserted into the
RBC membrane are functionally equivalent (with regard to
their interaction with HIV-1) to native CD4 expressed on the
T-cell surface, we evaluated three functions normally asso-
ciated with membrane-bound viral receptors: (i) their ability
to mediate HIV-1 entry; (ii) their ability to inhibit infection of
CD4-positive T cells with cell-free HIV-1; and (iii) their
ability to mediate the aggregation with HIV-1-infected T
cells.
The potential of CD4 exposed on the RBC surface to
mediate HIV-1 binding and entry was determined by using
the membrane fluorescence DQ technique (15-19). HIV-1
fused in a cell-number-dependent manner with human RBC-
CD4 but not with control human RBCs (Fig. 3). Results of
two separate experiments using different preparations of
RBC-CD4 and labeled virions are shown. The DQ value
obtained with 25 x 106 RBC-CD4 was equivalent to that
obtained with 2 x 106 CD4-positive CEM or CR10 cells (Fig.
3). This is consistent with the 2000 CD4 epitopes per RBC
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FIG. 2. Life-span measurements, in rabbits, of '25I-CD4 or 125I-
glycophorin inserted in RBC membrane. The RBCs were labeled
with 51Cr. Epitopes were assayed by flow cytometry with unlabeled
CG4 as control. At the indicated time points, 1.5 ml of blood was
drawn from the marginal ear vein of the rabbit and its radioactivity
was measured in a y counter (Packard model 5002).
2(-
11
a
r
= ~=~
=
1= =
x x x x x x x x
RBC RBC-CD4 CEM CR10
control
C>
6r2
-= -I = = = -
X X X X X X;X
= kr. r= ! n = r4
_
C1 I r] , ri
I
RBC | B-Ijl)4 RBC-CD4: (C-NI
control KT4A.
FIG. 3. Measurement of fusion between HIV-1 and RBC-CD4 by
the membrane fluorescence DQ. Purified R-18-labeled HIV-1 was
incubated with the designated amounts of RBC-CD4, RBC-CD4
saturated with OKT4A mAb, control RBC, or CD4-positive cell lines
CEM and CR10 as controls. (a and b) Results of two separate
experiments.
versus about 50,000 CD4 molecules per CEM cell (12).
Fusion of HIV-1 with RBC-CD4, like that with CEM, oc-
curred at 37°C but not 4°C and had a half-DQ time of5-8 min
at 37°C. It is noteworthy that pretreatment ofRBC-CD4 with
OKT4A antibodies significantly reduced the DQ (Fig. 3b).
This suggests that the binding and fusion of HIV-1 with
RBC-CD4 are mediated by the same functional region(s) of
the CD4 molecule that serve as the HIV receptor on T cells.
Inhibition ofHIV Infection ofTarget Cells by RBC-CD4. We
next examined the capacity ofRBC-CD4 to block infection in
vitro with cell-free HIV-1. RBC-CD4, RBC-CD4/OKT4A,
RBCs, orCEM cells were incubated with HIV-11IB for 30 min
at 37°C, the cells were removed by low-speed centrifugation,
and supernatants were filtered through 0.45-,m Millipore
filters. Filtered supernatants were then used for infection of
target CD4-positive T cells by a standard protocol (19). Fig.
4 shows the results of experiments of inhibition of HIV-1
infection by RBC-CD4. Clearly, pretreatment with either
RBC-CD4 or CEM cells reduced the infectious titer ofHIV-1
Biophysics: Zeira et al.
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scriptase. RBC-CD4 in which HIV-1-binding CD4 epitopes
were blocked with OKT4A antibodies were significantly less
effective in "clearing" infectious HIV (Fig. 4). Similar results
were obtained when C-8166 cells, which are exquisitely
susceptible to HIV infection, served as targets in these
experiments (Fig. 4b).
Aggregation of RBC-CD4 with HIV-Infected, gpl20-
Expressing CEM Cells. To evaluate whether RBC-CD4 can
interact with HIV-1-infected T lymphocytes, RBC-CD4 were
mixed with the chronically infected CEM/NIT-E (19) cells at
a ratio of 100:1 and examined under a light microscope after
5-10 min of incubation at 370C. Numerous aggregates be-
tween CEM/NIT-E cells and RBC-CD4, but not control
RBCs, were seen within a short time of incubation. Fusion
was observed between RBC-CD4 and T cells and occasion-
ally among T cells themselves (Fig. 5). RBC-CD4 do not
aggregate with uninfected CEM cells (not shown). Thus,
RBC-CD4 appear to recognize the native gp120 molecules on
the surface of HIV-1-infected cells and thus aggregate with
these cells. These observations confirm those made with
CHO cells constitutively expressing gpl20 and RBC-CD4
(20).
DISCUSSION
We have constructed a long-lived vehicle for the adsorption
and possible clearance of HIV-1 virions or infected gpl20-
expressing cells present in the circulation, RBCs bearing
electroinserted CD4. The electroinserted CD4 molecules are
accessible to interactions at the surface membrane, a require-
ment for binding HIV-1 (Fig. 1). In addition, by using
autologous RBCs as carriers, we have overcome one major
limitation which has been found in therapy with sCD4-its
relatively short lifetime in vivo (7). When inserted in rabbit
RBC membranes, the CD4 molecule acquires a half-life in the
circulation of 7 days (Fig. 2). The RBCs' half-life time in
circulation is not affected by the electroinsertion procedure,
U 16.
FIG. 4. Reduction in the infectivity of HIV-1 by preincubation
with the RBC-CD4. (a) Kinetics of intracellular HIV-1 antigen
expression after exposure ofCEM cells to HIV-1 preincubated with
RBC-CD4 (o), RBC-CD4 blocked with OKT4A (A), or untreated
RBC (o), as measured by immunofluorescence. (b) Supernatant p24
antigen concentrations in parallel experiment using C-8166 cells as
targets, assayed 6 days after infection. (c) Supernatant reverse
transcriptase on day 12 after infection of CEM cells.
present in the virus preparation 80-90% as assayed by
immunofluorescence of p24 or production of reverse tran-
FIG. 5. Interaction of RBC-CD4 with HIV-i-infected T lympho-
cytes. RBC-CD4 were mixed with chronically infected CEM/NIT-E
cells at 100:1 ratio and examined under a light microscope after 5-10
min ofincubation at 37°C. (a, b, and c) RBC-CD4 mixed with infected
CEM/NIT-E. Note in a and b the "rosetting" of RBC-CD4 around
the HIV-1-infected T cells. The picture shown in c was taken after
30-min incubation at 37°C. At this time giant cells began to form,
possibly after RBC-CD4 fused with CEM/NIT-E cells and the latter
were then able to fuse among themselves. Lysed erythrocyte
"ghosts" by arrowheads. (d) Control RBCs mixed with infected
CEM/NIT-E cells and incubated for 30 min. (Phase contrast, x 350.)
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similar to the observation of unchanged life spans of RBCs
subjected to electroporation (21).
Although we have previously characterized electroin-
serted CD4 as retaining the same epitope display as T-cell
surface CD4 (11), it was necessary to demonstrate that such
CD4 remained able to serve as an HIV-1 receptor. We
evaluated this by assay of virus-RBC membrane fusion
through membrane fluorescence DQ (Fig. 3). This method
has been previously demonstrated to accurately measure
HIV-1 binding and internalization (15-18). Indeed, HIV-1
fused specifically with RBC-CD4 but not with control RBCs.
That these interactions preserve the specificity of the native
CD4-gp120 recognition was demonstrated by the ability of
OKT4A mAb to block the entry of HIV-1 into RBC-CD4,
analogous to its ability to block HIV-1 binding to T lympho-
cytes (18). The fact that HIV-1 may be internalized by the
RBC carrier offers an additional advantage to ultimate ther-
apeutic application. It may be envisioned that RBC-CD4 can
absorb and internalize HIV-1, physically removing the par-
ticle from interactions with cells susceptible to infection.
We have shown that, consistent with the findings above,
RBC-CD4 absorb and thus reduce the infectious titer of
HIV-1, suggesting their potential as an efficient competitor
with target T lymphocytes for gp120 binding (Fig. 4). Finally,
another attribute of the RBC carrier of CD4 we have dem-
onstrated here is its ability to agglutinate HIV-1-infected
cells, through CD4-gpl2O binding (Fig. 5). These RBC-
lymphocyte aggregates would likely suffer phagocytosis in
the circulation.
In summary, RBCs as carriers for CD4 for neutralization of
HIV in vivo maintain the critical features of sCD4 that
recommended its clinical evaluation: the abilities to bind
HIV-1 and effectively compete with T cells for this binding
(2-7). Moreover, they have three distinct advantages over
sCD4: (i) their lifetime in the circulation is 7 days in rabbits,
compared to hours for adhesins (7); (ii) they internalize and
thus, for the life span of the RBC, irreversibly remove HIV-1
from potential interaction with susceptible cells; and (iii)
through their multivalent display ofCD4 they can agglutinate
gp120-displaying HIV-1 infected cells, which may result in
their clearance from the circulation. The latter finding is
noteworthy in that the currently available treatments for
HIV-1 infection depend upon blocking the infection of new,
uninfected cells (2-6); this agent also has the potential for
eliminating HIV-1-infected cells.
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